Ruilin He

Dr. Ruilin He


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
ZLZhixuan Lan
Zhixuan Lan
YWYi Wei
Yi Wei
KYKan Yue
Kan Yue
RHRuilin He
Ruilin He
ZJZongbin Jiang
Zongbin Jiang
Background: Previous observational studies have indicated a complex association between gut microbiota (GM) and neuropathic pain (NP). Nonetheless, the precise biological mechanisms underlying this association remain unclear. Therefore, we adopted a Mendelian randomization (MR) approach to investigate the causal relationship between GM and neuropathic pain including post-herpetic neuralgia (PHN), painful diabetic peripheral neuropathy (PDPN), and trigeminal neuralgia (TN), as well as to explore the potential mediation effects of immune cells. Methods: We performed a two-step, two-sample Mendelian randomization study with an inverse variance-weighted (IVW) approach to investigate the causal role of GM on three major kinds of NP and the mediation effect of immune cells between the association of GM and NP. In addition, we determine the strongest causal associations using Bayesian weighted Mendelian randomization (BWMR) analysis. Furthermore, we will investigate the mediating role of immune cells through a two-step Mendelian randomization design. Results: We identified 53 taxonomies and pathways of gut microbiota that had significant causal associations with NP. In addition, we also discovered 120 immune cells that exhibited significant causal associations with NP. According to the BWMR and two-step Mendelian randomization analysis, we identified the following results CD4 on CM CD4 + (maturation stages of T cell) mediated 6.7% of the risk reduction for PHN through the pathway of fucose degradation (FUCCAT.PWY). CD28 + DN (CD4-CD8-) AC (Treg) mediated 12.5% of the risk reduction for PHN through the influence on Roseburia inulinivorans. CD45 on lymphocyte (Myeloid cell) mediated 11.9% of the risk increase for TN through the superpathway of acetyl-CoA biosynthesis (PWY.5173). HLA DR + CD8br %T cell (TBNK) mediated 3.2% of the risk reduction for TN through the superpathway of GDP-mannose-derived O-antigen building blocks biosynthesis (PWY.7323). IgD-CD38-AC (B cell) mediated 7.5% of the risk reduction for DPN through the pathway of thiazole biosynthesis I in E. coli (PWY.6892). Discussion: These findings provided evidence supporting the causal effect of GM with NP, with immune cells playing a mediating role. These findings may inform prevention strategies and interventions directed toward NP. Future studies should explore other plausible biological mechanisms.

14 January 2026 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
KYKan Yue
Kan Yue
XLXinyu Lei
Xinyu Lei
RHRuilin He
Ruilin He
ZJZongbin Jiang
Zongbin Jiang

1 December 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
XLXiaoxiao Lan
Xiaoxiao Lan
XHXin Hu
Xin Hu
ZLZhixuan Lan
Zhixuan Lan
LWLiu Wang
Liu Wang
RHRuilin He
Ruilin He
ZJZongbin Jiang
Zongbin Jiang
Introduction: Insomnia is one of the most common complications in cancer patients, and Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for insomnia in the general population and patients with a cancer diagnosis. Traditional CBT-I is susceptible to limitations such as geography, physical condition, and cost of access to healthcare, hindering its widespread adoption. With the application and development of digitalization and artificial intelligence providing opportunities for the administration and promotion of Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I) to provide a better sleep treatment option for cancer pain patients, this study aims to evaluate its efficacy. Methods: This single-center trial will randomize 158 cancer pain patients with insomnia to DCBT-I or sleep hygiene education (1:1) to test if DCBT-I is superior for improving sleep quality. Assessments will also cover pain intensity, mental health, and quality of life. Discussion: This study will provide valuable clinical evidence that DCBT-I helps to improve sleep quality, pain intensity, mental health, and quality of life in cancer pain patients suffering from insomnia and contributes to the dissemination of this non-pharmacological alternative treatment option. Conclusion: This study protocol outlines a rigorous randomized controlled trial to evaluate the efficacy of Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I) compared to Sleep Hygiene Education (SHE) in cancer pain patients with comorbid insomnia. The Resleep smartphone-based intervention integrates evidence-based CBT-I components (sleep restriction, stimulus control, cognitive restructuring, and relaxation training) to address the limitations of traditional therapy, such as accessibility and cost. Clinical Trial Registration: This study is a registered clinical trial. Registry: Chinese Clinical Trial Registry (ChiCTR), listed in the WHO International Clinical Trials Registry Platform (WHO ICTRP). Trial Registration Number: ChiCTR2500096855. Date of Registration: 07 February 2025. Registration Url: https://www.chictr.org.cn/index.html.

9 October 2025 in International Journal of Pain Research
Verified
Journal Article
Open access
PDF file
YKYue Kan
Yue Kan
ZJZongbin Jiang
Zongbin Jiang
RHRuilin He
Ruilin He
XSXu Shengrong
Xu Shengrong
ZZZhou Zenghua
Zhou Zenghua
FBFan Bifa
Fan Bifa
Phantom limb pain (PLP), defined as neuropathic pain perceived in the missing portion of an amputated limb, represents a common and refractory condition significantly impairing patient rehabilitation and quality of life. Its pathogenesis is multifactorial, involving complex interactions between peripheral mechanisms (e.g., neuroma formation, ectopic discharges), central nervous system reorganization (including cortical remapping and spinal cord sensitization), and psychological components. Patients frequently present with heterogeneous pain descriptors, such as burning, shooting, or cramping sensations, which often coexist with residual limb pain, complicating clinical assessment. Despite the availability of diverse therapeutic interventions-ranging from pharmacotherapy (e.g., gabapentinoids, antidepressants, NMDA receptor antagonists) and physical modalities (e.g., transcranial magnetic stimulation, mirror therapy) to interventional procedures (e.g., nerve blocks, neuromodulation) and psychological approaches-treatment outcomes remain variable, and standardized clinical guidelines are lacking. This consensus, formulated by a panel of Chinese pain specialists, systematically reviews contemporary evidence on the epidemiology, pathophysiology, diagnosis, and management of PLP. It aims to establish practical, evidence-based recommendations to guide the standardized diagnosis and stratified treatment of PLP, thereby optimizing therapeutic efficacy and improving functional outcomes for affected individuals.

24 November 2025 in Hematology
Verified
Journal Article
Open access
YCYongyu Chen
Yongyu Chen
BLBin Liang
Bin Liang
RHRuilin He
Ruilin He
ZZZhongming Zhang
Zhongming Zhang
Acute myeloid leukemia (AML) exhibits significant heterogeneity and aggressiveness. This study aimed to investigate T cell heterogeneity in the AML tumor microenvironment using single-cell RNA sequencing (scRNA-seq) and identify potential biomarkers for prognosis and precision therapy. scRNA-seq data from AML patient samples were analyzed to identify T cell subsets. A prognostic risk model was constructed using random forest and LASSO regression analyses based on key genes derived from a specific T cell cluster (Cluster 4). The model's predictive performance was validated using external datasets. Analysis revealed significant functional heterogeneity among T cell subsets. Cluster 4 T cells showed distinct gene set activities related to immune regulation. Three genes - BSG, PPARD, and SLC16A8 - were identified as independent prognostic factors. The risk model effectively stratified patients into high-risk and low-risk groups, with the high-risk group demonstrating significantly poorer survival outcomes. The model showed robust predictive accuracy, with areas under the ROC curve of 0.78, 0.86, and 0.86 for 1-, 3-, and 5-year survival, respectively. This study highlights the functional diversity of T cells in AML and identifies BSG, PPARD, and SLC16A8 as promising biomarkers for prognostic stratification. The developed risk model provides a valuable tool for guiding personalized treatment strategies in AML.